Regeneron: the annual R&D commitment
Regeneron raises GAAP R&D guidance to $6.600B–$6.735B. The midpoint measures recorded research expense without implying that more spending guarantees pipeline success.
Regeneron Pharmaceuticals / REGNPublic biotechR&D-spendingDate to watch
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
Primary evidence
Reporting date unconfirmed — research candidate
Regeneron Q3 2026 operating and financial resultsPublished 2026-10-30
Potential outcome market
Will Regeneron 2026 GAAP R&D expense exceed $6.6675 billion?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.